Mixed-Phenotype Acute Leukemia: Clinical Diagnosis and Therapeutic Strategies

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Aug 26

PMID 36009521

Authors

Binsah S George

Binoy Yohannan

Anneliese Gonzalez

Adan Rios

Affiliations

Soon will be listed here.

Abstract

Mixed-phenotype acute leukemia (MPAL) comprises a heterogenous group of leukemias that are genetically, immunophenotypically, and clinically, diverse. Given the rarity of the disease, the diagnosis and treatment of MPAL is extremely challenging. Recent collaborative efforts have made significant progress in understanding the complex genomic landscape of MPAL. Some retrospective studies support starting ALL-type induction followed by an allogeneic stem cell transplant(allo-sct) in the first complete remission; however, due to the inherent bias of retrospective data and small case series, a prospective validation of AML- and ALL-based regimen, and the incorporation of targeted therapies based on genetics and immunophenotype are warranted. The prognosis of adults and children with MPAL varies; this justifies modulating the intensity of therapy, including the use of allo-sct as a consolidation strategy.

Citing Articles

Flow cytometric characterisation of acute leukaemia in adolescent and adult Ethiopians.

Alemu J, Gumi B, Tsegaye A, Sherif A, Tadesse F, Gebremedhin A Afr J Lab Med. 2025; 14(1):2394.

PMID: 39968161 PMC: 11830883. DOI: 10.4102/ajlm.v14i1.2394.

Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias.

Niscola P, Gianfelici V, Giovannini M, Piccioni D, Mazzone C, de Fabritiis P Cancers (Basel). 2025; 17(1.

PMID: 39796769 PMC: 11720583. DOI: 10.3390/cancers17010142.

Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia.

Peretz C, Kennedy V, Walia A, Delley C, Koh A, Tran E Nat Commun. 2024; 15(1):8191.

PMID: 39294124 PMC: 11411136. DOI: 10.1038/s41467-024-52317-2.

Leukemia cutis as an initial presentation in a case of mixed phenotype acute leukemia: a double jeopardy.

Stephen N, Jeyaraman R, Srinivas B, Dileep J, Nagendran P, Manivannan P Int J Clin Exp Pathol. 2024; 17(8):252-256.

PMID: 39262435 PMC: 11384332. DOI: 10.62347/ACDG7634.

Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report.

Li K, Wang Y, Pei R, Lu Y, Cao J, Zhuang X Turk J Haematol. 2024; 41(3):202-204.

PMID: 39078014 PMC: 11589369. DOI: 10.4274/tjh.galenos.2024.2024.0044.

References

Durer S, Durer C, Shafqat M, Comba I, Malik S, Faridi W . Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. Immunotherapy. 2019; 11(5):373-378. PMC: 6439498. DOI: 10.2217/imt-2018-0104. View

Wolach O, Stone R . Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015; 21(19):4262-9. DOI: 10.1158/1078-0432.CCR-15-0125. View

Tremblay Z, Wong A, Otis A, Pepin M, Bambace N, Soulieres D . Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series. Eur J Haematol. 2021; 108(2):163-165. DOI: 10.1111/ejh.13717. View

Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N . A classification of acute leukaemia for the 1990s. Ann Hematol. 1991; 62(1):16-21. DOI: 10.1007/BF01714978. View

Charles N, Boyer D . Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls. Arch Pathol Lab Med. 2017; 141(11):1462-1468. DOI: 10.5858/arpa.2017-0218-RA. View

Zhang Y, Wu D, Sun A, Qiu H, He G, Jin Z . Clinical characteristics, biological profile, and outcome of biphenotypic acute leukemia: a case series. Acta Haematol. 2011; 125(4):210-8. DOI: 10.1159/000322594. View

Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A . Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017; 102(12):2134-2140. PMC: 5709113. DOI: 10.3324/haematol.2017.174441. View

Austin G, Alvarado C, Austin E, Hakami N, Zhao W, CHAUVENET A . Prevalence of myeloperoxidase gene expression in infant acute lymphocytic leukemia. Am J Clin Pathol. 1998; 110(5):575-81. DOI: 10.1093/ajcp/110.5.575. View

Wang N, He J, Liu F . Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases. Chemotherapy. 2022; 67(3):178-182. DOI: 10.1159/000519882. View

10.

Bene M, Castoldi G, Knapp W, Ludwig W, Matutes E, Orfao A . Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995; 9(10):1783-6. View

11.

Raikar S, Park S, Leong T, Jaye D, Keller F, Horan J . Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival. Blood. 2017; 131(5):573-577. DOI: 10.1182/blood-2017-09-807602. View

12.

Ball E, Davis R, Griffin J, Mayer R, Davey F, Arthur D . Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991; 77(10):2242-50. View

13.

Zhou M, Findley H, Zaki S, Little F, Coffield L, Ragab A . Expression of myeloperoxidase mRNA by leukemic cells from childhood acute lymphoblastic leukemia. Leukemia. 1993; 7(8):1180-3. View

14.

Janossy G, Coustan-Smith E, Campana D . The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 1989; 3(3):170-81. View

15.

Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge D, Rosenthal J . CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019; 3(22):3539-3549. PMC: 6880911. DOI: 10.1182/bloodadvances.2019000692. View

16.

Li M, Lin Z, Hu M, Kang L, Wu X, Chen Q . Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report. Biomark Res. 2020; 8:36. PMC: 7457525. DOI: 10.1186/s40364-020-00216-1. View

17.

Brethon B, Lainey E, Caye-Eude A, Grain A, Fenneteau O, Yakouben K . Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a -Rearranged Leukemia. Front Oncol. 2021; 11:637951. PMC: 7953899. DOI: 10.3389/fonc.2021.637951. View

18.

Wolach O, Amitai I, DeAngelo D . Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia. Br J Haematol. 2017; 179(5):705-723. DOI: 10.1111/bjh.14916. View

19.

Bene M, Lacombe F, Porwit A . Unsupervised flow cytometry analysis in hematological malignancies: A new paradigm. Int J Lab Hematol. 2021; 43 Suppl 1:54-64. DOI: 10.1111/ijlh.13548. View

20.

Rossi J, Bernasconi A, Alonso C, Rubio P, Gallego M, Carrara C . Lineage switch in childhood acute leukemia: an unusual event with poor outcome. Am J Hematol. 2012; 87(9):890-7. DOI: 10.1002/ajh.23266. View